Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective
Stock Information for Sonnet BioTherapeutics Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.